ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Standards Program
The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Latest Magazine Issues
Dec 2025
Jul 2025
Latest Journal Issues
Nuclear Science and Engineering
January 2026
Nuclear Technology
December 2025
Fusion Science and Technology
November 2025
Latest News
Christmas Light
’Twas the night before Christmas when all through the house
No electrons were flowing through even my mouse.
All devices were plugged by the chimney with care
With the hope that St. Nikola Tesla would share.
Victor R. Prybutok, Leonard M. Gold
Nuclear Technology | Volume 78 | Number 3 | September 1987 | Pages 303-311
Nuclear Power Plant Kalkar (SNR-300) | Nuclear Safety | doi.org/10.13182/NT87-A15996
Articles are hosted by Taylor and Francis Online.
The leukemia incidence risk for a single coal plant, a single nuclear plant, and a single nuclear accident is used to compute the total industry leukemia incidence risk. In the absence of a nuclear power plant accident, the leukemia incidence risk is normally lower for a nuclear industry than for a coal industry of equivalent size. The nuclear industry risk with accidents was compared to the coal industry risk for six proposed dose response curves. Simplifying assumptions about the negligible effect of the cell-killing term and the linear nature of the linear quadratic curve allowed derivation of risk models for the assumption of both linear and quadratic dose response. These derived models, representing leukemia incidence risk bounds, are used to estimate the total industry risk comparison. Evaluation of an accident’s impact on the leukemia incidence risk comparison is done with the risk bounds and compared to the risk evaluations calculated during all six dose response curves. The overlapping plot of the number of nuclear accidents required for equivalent industry environmental risks versus the accident fraction allows the conservative function to be defined.